Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons

American Journal of Clinical Nutrition

Volumn 84, Issue 5, 2006, Pages 1003-1008

  Kassis, Amira N ^a   Jones, Peter J H ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Cholesterol lowering effect; Double blind crossover study design; Hypercholesterolemic persons; LDL cholesterol; Sugar cane policosanols

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CUBA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EATING HABIT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SUGARCANE;

ANIMALIA; SACCHARUM;

EID: 33750908247     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/84.5.1003     Document Type: Article

References (51)

1. Aneiros E, Mas R, Calderon B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res Exp 1995;56:176-82.
2. Batista J, Stusser R, Saez F, Perez B. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study. Int J Clin Pharmacol Ther 1996;34:134-7.
3. Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez JC. Effects of policosanol on primary hypercholesterolemia: a 3-year open-extension follow-up. Curr Ther Res Clin Exp 1997;58:868-75.
4. Canetti M, Moreira M, Illnait J, et al. One-year study of the effect of policosanol on lipid profile in patients with type II hypercholesterolemia. Adv Ther 1995;12:245-54.
5. Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15:159-65.
6. Castano G, Canetti M, Moreira M. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. Curr Ther Res Clin Exp 1995;56:819-28.
7. Castano G, Mas R, Nodarse M, Illnait J, Fernandez JC. One-year of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res Clin Exp 1995;56:296-303.
8. Castano G, Fernandez L, Mas R, et al. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res 2002;22:55-66.
9. Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez J. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidemia and type 2 diabetes mellitus. Clin Drug Invest 2003;23:639-50.
10. Castano G, Mas Ferreiro R, Fernandez L, Gamez R, Illnait J, Fernandez C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 2001;52:115-25.
11. Castano G, Mas R, Arruzazabala ML, et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999;19:105-16.
12. Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001;56:M186-92.
13. Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000;14:187-95.
14. Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 2001;21:43-57.
15. Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003;20:153-63.
16. Castano G, Mas R, Gamez R, et al. Concomitant use of policosanol and beta-blockers in older patients. Int J Clin Pharmacol Res 2004;24:65-77.
17. Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002;22:89-99.
18. Crespo N, Alvarez R, Mas R, Illnait J, Fernandez L, Fernandez JC. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study. Curr Ther Res 1997;58:44-51.
19. Fernandez J, Mas R, Castano G, et al. Comparison of the efficacy, safety and tolerability of policosanol versus Fluvastatin in elderly hypercholesterolemic women. Clin Drug Invest 2001;21:103-13.
20. Mas R, Castano G, Fernandez L, Illnait J, Fernandez J, Alvarez E. Clinical use: effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease. Clin Drug Invest 2001;21:485-99.
21. Castano G, Menendez R, Mas R, et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res 2002;22:89-99.
22. Crespo N Alvarez R, Mas R, Illnait J, Fernandez L, Fernandez JC. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: a pilot study. Curr Ther Res. 1997;58:44-51.
23. Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999;65:439-47.
24. Mirkin A, Mas R, Martinto M, et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 2001;21:31-41.
25. Ortensi G, Gladstein J, Valli H, Testone P. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res Clin Exp 1997;58:390-401.
26. Pons P, Mas R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia. Curr Ther Res Clin Exp 1992;52:507-13.
27. Pons P, Rodriguez M, Mas R, et al. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1994;55:1084-92.
28. Pons P, Rodriguez M, Robaina C. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14:27-33.
29. Varady KA, Wang Y, Jones PJ. Role of policosanols in the prevention and treatment of cardiovascular disease. Nutr Rev 2003;61:376-83.
30. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy 2005;25:171-83.
31. Reiner Z, Tedeschi-Reiner E, Romic Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. Clin Drug Invest 2005;5:701-7.
32. Tedeschi-Reiner E, Reiner Z, Romic Z, Ivankovic D. A randomized, double-blind, placebo-controlled study of the antilipemic efficacy and tolerability of food supplement policosanol in patients with moderate hypercholesterolemia. Lijec Vjesn 2005;127:273-9 (in Croatian).
33. Lin Y, Rudrum M, van der Wielen RP, et al. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 2004;53:1309-14.
34. Greyling A, De Witt C, Oosthuizen W, Jerling JC. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 2006;95:968-75.
35. Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
36. Menendez R, Amor AM, Gonzalez RM, Fraga V, Mas R. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res 1996;29:253-7.
37. Murphy KJ, Saint DA, Howe PR. Lack of effect of sugar cane and sunflower seed policosanols on plasma cholesterol in rabbits. Asia Pac J Clin Nutr 2004;13(suppl):S69 (abstr).
38. Arruzazabala ML, Carbajal D, Mas R, Molina V, Castano G, Gamez R. Effects of D-003, a new compound purified from sugarcane wax, on platelet aggregation in healthy volunteers. Clin Drug Invest 2003;23:107-18.
39. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006;295:2263-9.
40. Jones PJ, Ntanios FY, Raeini-Sarjaz M, Vanstone CA. Cholesterol-lowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic men. Am J Clin Nutr 1999;69:403-10.
41. Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr 2002;76:1272-8.
42. Denke MA. Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterol-lowering diet in men with moderate hypercholesterolemia. Am J Clin Nutr 1995;61:392-6.
43. Jones PJ, Vanstone CA, Raeini-Sarjaz M, St-Onge MP. Phytosterols in low- and nonfat beverages as part of a controlled diet fail to lower plasma lipid levels. Am J Clin Nutr 2003;69:1144-50.
44. Uribarri E, Laguna A, Sierra R, Ricardo Y. Physico-mechanical characterization of policosanol, a novel hypocholesterolemic drug. Drug Dev Ind Pharm 2002;28:89-93.
45. Hargrove JL, Greenspan P, Hartle DK. Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes. Exp Biol Med (Maywood) 2004;229:215-26.
46. Kabir Y, Kimura S. Tissue distribution of (8-14C)-octacosanol in liver and muscle of rats after serial administration. Ann Nutr Metab 1995;39:279-84.
47. Menendez R, Amor AM, Rodeiro I, et al. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 2001;32:8-12.
48. Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-32.
49. Menendez R, Arruzazabala L, Mas R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 1997;77:923-32.
50. Mannaerts GP, Van Veldhoven PP, Casteels M. Peroxisomal lipid degradation via beta- and alpha-oxidation in mammals. Cell Biochem Biophys 2000;32:73-87.
51. Menendez R, Marrero D, Mas R, Fernandez I, Gonzalez L, Gonzalez RM. In vitro and in vivo study of octacosanol metabolism. Arch Med Res 2005;36:113-9.